Skip to content

Titan Pharmaceuticals, Inc.

CIK 0000910267

← back to feed
Revenue (TTM)
$6.33M
+28.5% YoY Q2 Aug 2025
Net Income (TTM)
−$4.11M
+15.5% YoY Q2 Aug 2025
EPS Diluted (TTM)
−$4.39
+29.4% YoY Q2 Aug 2025
Gross Margin
98.6%
Q2 Aug 2025
Operating Margin
-63.5%
Q2 Aug 2025
Net Margin
-64.9%
Q2 Aug 2025
Free Cash Flow (TTM)
−$6.48M
Q2 Aug 2025
Cash
$2.8M
Q2 Aug 2025
Total Debt
$0
Q2 Aug 2025
Shares Outstanding
1.33M sh
Q2 Aug 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings